Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.67 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.46 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081621 | 0.87 | MTNR1A (0.64) | MTNR1AMTNR1BROCK2HTR1AADRA1D | |
| SCHEMBL591578 | 0.86 | MTNR1A (0.62) | MTNR1AMTNR1BROCK2HTR1AADRA1D | |
| SCHEMBL6378710 | 0.86 | MTNR1A (0.62) | MTNR1AMTNR1BROCK2HTR1AADRA1D | |
| SCHEMBL5503877 | 0.86 | MTNR1A (0.66) | MTNR1AMTNR1BROCK2HTR1AADRA1D | |
| SCHEMBL2095739 | 0.86 | MTNR1A (0.52) | MTNR1AMTNR1BROCK2HTR1AADRA1D | |
| SCHEMBL20542004 | 0.84 | MTNR1A (0.63) | MTNR1AMTNR1BROCK2HTR1AADRA1D | |
| SCHEMBL3003009 | 0.83 | MTNR1A (0.58) | MTNR1AMTNR1BROCK2HTR1AADRA1D | |
| SCHEMBL2544860 | 0.83 | MTNR1A (0.61) | MTNR1AMTNR1BROCK2HTR1AADRA1D | |
| SCHEMBL27609303 | 0.83 | MTNR1A (0.58) | MTNR1AMTNR1BROCK2HTR1AADRA1D | |
| SCHEMBL591421 | 0.83 | MTNR1A (0.58) | MTNR1AMTNR1BROCK2HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | MTNR1A 802/4885MTNR1B 707/4885ROCK2 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.